<DOC>
	<DOCNO>NCT00721344</DOCNO>
	<brief_summary>48 healthy adult male &amp; female subject enrol study determine effect Technosphere速 Inhalation Powder ( FDKP ) QT interval EKG . Eligible subject randomize dose regimen admission .</brief_summary>
	<brief_title>A Study Determine Technosphere速 Inhalation Powder ( FDKP ) Causes ECG Changes ( QTc ) Following Medication 's Inhaled Administration .</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , cross-over , placebo- active-controlled cardiac safety study 48 healthy subject ( male female subject ) design assess effect FDKP cardiac repolarization , , follow introduction Technosphere速 Inhalation Powder via inhalation . Each trial subject administer 20 mg FDKP , 40 mg FDKP , 400 mg oral dose moxifloxacin ( active ) , placebo crossover design 11 day in-patient stay .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Pulmonary Function Tests ( PFTs ) result within study specify limit . Female subject childbearing potential must nonpregnant nonlactating negative serum pregnancy test prior enrollment trial . Body Mass Index = 19 = 30 kg/m2 Absence recent drug alcohol abuse Able provide write informed consent , follow study procedure remain inpatient entire treatment period Nonsmoking ( &gt; 6 month ) History significant renal , pulmonary , rheumatological , hematological , neurological psychiatrics disorder Clinically significant major organ disease Evidence history clinically significant allergy ( except untreated , asymptomatic , seasonal allergy time dose ) ; Current previous chemotherapy radiation therapy could cause lung toxicity History diabetes take medication treat diabetes Clinically significant abnormal finding physical exam , ECG , vital sign , clinical laboratory test medical history Hypokalemia ( calcium lower limit normal ) . Previous exposure Technosphere速 Inhalation Powder Participation another clinical trial investigational drug device within 30 day prior Visit 3 Significantly excessive consumption food beverage xanthine caffeine Unwilling avoid alcohol 48 hour prior study enrollment study Unwilling avoid strenuous activity 48 hour prior study enrollment study Positive HIV Hepatitis test Any acute illness fever within 72 hour study dose Medication use ( exception acetaminophen hormonal birth control ) herbal use within 7 day Visit 2 Unwillingness remain quiet , control environment ( i.e. , TV , music , game , etc specific timepoints ) unwilling remain supine specific timepoints Unwillingness consume studyspecific diet Blood donation within 8 week prior Visit 2 History chronic obstructive pulmonary disease ( COPD ) , clinically proven asthma and/or clinically important pulmonary disease confirm pulmonary function test and/or radiological find Active respiratory infection persistent symptom infection History risk factor Torsades de pointes ( TdP ) [ e.g. , heart failure , hypokalemia , family history ( parent sibling ) Long QT Syndrome ] , history fainting , unexplained loss consciousness convulsion History cardiac arrhythmia , take antiarrhythmia drug , significant cardiovascular dysfunction , myocardial dysfunction , cardiac surgery , transient attack ischemia cerebrovascular accident An abnormal screening ECG interpret Clinical Site Investigator clinically significant Sustained supine rest systolic blood pressure &gt; 140 mm Hg &lt; 100 mm Hg /or diastolic blood pressure &gt; 95 mm Hg study entry Baseline pulse rate &lt; 45 beat per minute &gt; 100 beat per minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Healthy male female</keyword>
</DOC>